Inhibition of Colony Formation of Drug-resistant Human Tumor Cell Lines by Combinations of Interleukin-2-activated Killer Cells and Antitumor Drugs
Open Access
- 1 March 1989
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 80 (3) , 265-270
- https://doi.org/10.1111/j.1349-7006.1989.tb02303.x
Abstract
The cytotoxicity of interleukin‐2‐activated killer (LAK) cells with or without anticancer drugs against cell lines with acquired drug resistance was evaluated in vitro by colony assay. Human non‐small cell lung cancer cell lines, PC‐9 and PC‐14, human leukemia cell line, K‐562, and their sublines resistant to cisplatin (CDDP), PC‐9/CDDP and PC‐14/CDDP, and to adriamycin (ADM), K‐562/ADM, were used as target cells. PC‐9/CDDP demonstrated a marked increase in susceptibility to killing by both peripheral blood lymphocytes (PBL) and LAK cells, as compared to the parental cell line, PC‐9. The cytotoxicity of PBL and LAK cells against PC‐14/CDDP and K‐562/ADM was similar to that against their parental cell lines. Moreover, the combination of LAK and CDDP had a synergistic effect on PC‐14 and PC‐14/CDDP.Keywords
This publication has 17 references indexed in Scilit:
- Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell linesInternational Journal of Cancer, 1988
- Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin‐2 activated killer cells and by activated monocytesInternational Journal of Cancer, 1987
- Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.Proceedings of the National Academy of Sciences, 1986
- Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cells lines by Human Tumor Clonogenic Assay (HTCA)European Journal of Cancer and Clinical Oncology, 1986
- Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.Journal of Clinical Investigation, 1986
- Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycinInternational Journal of Immunopharmacology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletionBiochemical Pharmacology, 1985
- In vitro systems for evaluation of combination chemotherapyPharmacology & Therapeutics, 1980
- Primary Bioassay of Human Tumor Stem CellsScience, 1977